Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (MODULATE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03647839 |
|
Recruitment Status :
Completed
First Posted : August 27, 2018
Last Update Posted : August 27, 2021
|
Sponsor:
Australasian Gastro-Intestinal Trials Group
Information provided by (Responsible Party):
Australasian Gastro-Intestinal Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | January 29, 2021 |
| Actual Study Completion Date : | April 9, 2021 |